Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Igal Kushnir

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
European Journal of Clinical Investigation|September 29, 2011
Estimation of left ventricular function using a novel acoustic-based deviceNaira Radzievsky, Surik Papyan, Igal Kushnir, et al.
Cancer Chemotherapy and Pharmacology|April 3, 2020
Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancerIgal Kushnir, Ranjeeta Mallick, Michael Ong, et al.
Medical Oncology (Northwood, London, England)|January 23, 2019
The timing of docetaxel initiation in metastatic castrate-sensitive prostate cancer and the rate of chemotherapy-induced toxicityIgal Kushnir, Kim Koczka, Michael Ong, et al.
Wounds : a Compendium of Clinical Research and Practice|May 3, 2018
Safety and Efficacy of an Autologous Blood Clot Product in the Management of Texas 1A or 2A Neuropathic Diabetic Foot Ulcers: A Prospective, Multicenter, Open Label Pilot StudyRobert J Snyder, Maria A Kasper, Keyur Patel, et al.
Cancer Medicine|November 18, 2022
A population-based study of factors associated with systemic treatment in advanced prostate cancer decedentsJennifer Leigh, Danial Qureshi, Ewa Sucha, et al.
Nutrients|December 28, 2021
Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II StudyDaniel Keizman, Moshe Frenkel, Avivit Peer, et al.
Nutrients|August 26, 2023
Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II StudyDaniel Keizman, Moshe Frenkel, Avivit Peer, et al.
European Journal of Cancer (Oxford, England : 1990)|October 7, 2020
A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancerMark Clemons, Michael Ong, Carol Stober, et al.
Frontiers in Oncology|June 9, 2023
Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysisKeren Rouvinov, Eran Levanon, Avivit Peer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 21, 2019
Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate CancerElie Ritch, Simon Y F Fu, Cameron Herberts, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
European Journal of Clinical Investigation|September 29, 2011
Estimation of left ventricular function using a novel acoustic-based deviceNaira Radzievsky, Surik Papyan, Igal Kushnir, et al.
Cancer Chemotherapy and Pharmacology|April 3, 2020
Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancerIgal Kushnir, Ranjeeta Mallick, Michael Ong, et al.
Medical Oncology (Northwood, London, England)|January 23, 2019
The timing of docetaxel initiation in metastatic castrate-sensitive prostate cancer and the rate of chemotherapy-induced toxicityIgal Kushnir, Kim Koczka, Michael Ong, et al.
Wounds : a Compendium of Clinical Research and Practice|May 3, 2018
Safety and Efficacy of an Autologous Blood Clot Product in the Management of Texas 1A or 2A Neuropathic Diabetic Foot Ulcers: A Prospective, Multicenter, Open Label Pilot StudyRobert J Snyder, Maria A Kasper, Keyur Patel, et al.
Cancer Medicine|November 18, 2022
A population-based study of factors associated with systemic treatment in advanced prostate cancer decedentsJennifer Leigh, Danial Qureshi, Ewa Sucha, et al.
Nutrients|December 28, 2021
Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II StudyDaniel Keizman, Moshe Frenkel, Avivit Peer, et al.
Nutrients|August 26, 2023
Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II StudyDaniel Keizman, Moshe Frenkel, Avivit Peer, et al.
European Journal of Cancer (Oxford, England : 1990)|October 7, 2020
A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancerMark Clemons, Michael Ong, Carol Stober, et al.
Frontiers in Oncology|June 9, 2023
Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysisKeren Rouvinov, Eran Levanon, Avivit Peer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 21, 2019
Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate CancerElie Ritch, Simon Y F Fu, Cameron Herberts, et al.
Pageof 3